Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07809724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder

StatusNot Yet Recruiting
PhasePhase 2
Started2026-08-30
View on ClinicalTrials.gov ↗
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and improve the peripheral Treg/Th17 balance, thus restoring immune homeostasis. Studies have demonstrated a positive correlation between the Th17/Treg ratio and the severity of various autoimmune diseases. Clinically, low-dose IL-2 has been successfully used in the treatment of diseases such as systemic lupus erythematosus and Sjögren's syndrome. However, the efficacy and safety of IL-2 in neuromyelitis optica spectrum disorder (NMOSD) remain unknown. This clinical trial aims to investigate the safety and biological efficacy of IL-2 in treating NMOSD.
Trial Details
NCT Number NCT07809724
Lead Sponsor Peking University People's Hospital
Collaborators: Peking University First Hospital
Conditions Neuromyelitis Optica Spectrum Disorder (NMOSD)
Enrollment 60 participants
Start Date 2026-08-30
Primary Completion 2028-08-15 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-09